Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2020

01-06-2020 | Obesity | Research article

Association Between Metabolic Syndrome and Diabetes Mellitus According to International Diabetic Federation and National Cholesterol Education Program Adult Treatment Panel III Criteria: a Cross-sectional Study

Authors: Merlit James, Treesa P. Varghese, Raghav Sharma, Sharad Chand

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2020

Login to get access

Abstract

Purpose

Lifestyle changes in diabetes mellitus leads to metabolic syndrome, thus resulting in a hike in micro and macrovascular complications in diabetes mellitus patients. The main objective of the study was to identify the occurrence of metabolic syndrome and to evaluate the gender-associated difference in each component of metabolic syndrome by using International Diabetic Federation (IDF) and National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)criteria.

Methods

This is a cross-sectional study conducted in 350 type II diabetes mellitus patients. All the study participants within 30–80 years were enrolled. Subjects with type I DM and pregnant women were excluded from the study.

Results

The occurrence of metabolic syndrome among the diabetic population was found to be 42.28% and 28.85% using the IDF and the NCEP ATP III criteria respectively. It was observed that the prevalence was found to be higher in females than males as per IDF and NCEP ATP III criteria and was found to be statistically significant (p < 0.001). Central obesity elevated blood pressure, and reduced high-density lipoprotein was significantly higher in female patients. The most frequently occurring risk factor in this study population was central obesity followed by hypertension. A comparative analysis of IDF and NCEP ATP III criteria implies that when compared to diabetes patients without metabolic syndrome, all the metabolic risk elements were significantly higher in diabetes patients with metabolic syndrome.

Conclusions

This study concluded that the occurrence of metabolic syndrome was dreadfully high among the diabetic population, especially among female subjects.
Literature
1.
go back to reference Khanal P, Mandar BK, Patil BM, Hullatti KK. In silico Antidiabetic Screening of Borapetoside C, Cordifolioside A and Magnoflorine. Indian J Pharm Sci. 2019; 81: 550 – 55. Khanal P, Mandar BK, Patil BM, Hullatti KK. In silico Antidiabetic Screening of Borapetoside C, Cordifolioside A and Magnoflorine. Indian J Pharm Sci. 2019; 81: 550 – 55.
2.
go back to reference Khanal P, Patil BM, Mandar BK, et al. Network pharmacology-based assessment to elucidate the molecular mechanism of anti-diabetic action of Tinospora cordifolia. Clin Phytosci. 2019;5:35.CrossRef Khanal P, Patil BM, Mandar BK, et al. Network pharmacology-based assessment to elucidate the molecular mechanism of anti-diabetic action of Tinospora cordifolia. Clin Phytosci. 2019;5:35.CrossRef
3.
go back to reference James M, Varghese TP, Vijayan A, Anagha PP, Muhas C, Hyder M. Link between Metabolic Syndrome and Diabetes Mellitus: A Pathophysiological Implication. Int J Sci Technol Res. 2019;11:1935–40. James M, Varghese TP, Vijayan A, Anagha PP, Muhas C, Hyder M. Link between Metabolic Syndrome and Diabetes Mellitus: A Pathophysiological Implication. Int J Sci Technol Res. 2019;11:1935–40.
4.
go back to reference Rezaianzadeh A, Namayandeh SM, Sadr SM. National Cholesterol Education Program Adult Treatment Panel III Versus International Diabetic Federation Definition of Metabolic Syndrome, Which One is Associated with Diabetes Mellitus and Coronary Artery Disease? Int J Prev Med. 2012;3:552–58.PubMedPubMedCentral Rezaianzadeh A, Namayandeh SM, Sadr SM. National Cholesterol Education Program Adult Treatment Panel III Versus International Diabetic Federation Definition of Metabolic Syndrome, Which One is Associated with Diabetes Mellitus and Coronary Artery Disease? Int J Prev Med. 2012;3:552–58.PubMedPubMedCentral
5.
go back to reference Faizal R, George L, Lakshmanan P, Varghese TP. Assesment of diabetes related quality of life and the impact of pharmaceutical care in its improvement. J Coastal Life Med. 2016: 4; 649 – 51. Faizal R, George L, Lakshmanan P, Varghese TP. Assesment of diabetes related quality of life and the impact of pharmaceutical care in its improvement. J Coastal Life Med. 2016: 4; 649 – 51.
6.
go back to reference Nsiah K, Shang O, Boateng KA, Mensah FO. Prevalence of metabolic syndrome in type 2 diabetes mellitus patients. Int J Appl Basic Med Res. 2015;5:133–38.CrossRef Nsiah K, Shang O, Boateng KA, Mensah FO. Prevalence of metabolic syndrome in type 2 diabetes mellitus patients. Int J Appl Basic Med Res. 2015;5:133–38.CrossRef
7.
go back to reference Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:3569.CrossRef Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:3569.CrossRef
8.
go back to reference Huang P. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2:231–37.CrossRef Huang P. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2:231–37.CrossRef
9.
go back to reference Felix Val K, Titty WK, Owiredu WK, Agyei Frimpong MT. Prevalence of metabolic syndrome and its components among diabetes patients in Ghana. J Biol Sci. 2008;8:105761. Felix Val K, Titty WK, Owiredu WK, Agyei Frimpong MT. Prevalence of metabolic syndrome and its components among diabetes patients in Ghana. J Biol Sci. 2008;8:105761.
10.
go back to reference Linu Mohan P, Jishnu NA, Remya PJ. Prevalence of metabolic syndrome in psychiatric OP patients in tertiary care hospital, Kerala. Indian J Pharm Pract. 2012;5:58–61. Linu Mohan P, Jishnu NA, Remya PJ. Prevalence of metabolic syndrome in psychiatric OP patients in tertiary care hospital, Kerala. Indian J Pharm Pract. 2012;5:58–61.
11.
go back to reference Mawlieh BS, Shastry CS, Chand S. Evaluation of anti-diabetic activity of two marketed herbal formulations. Research J Pharm Tech. 2020;13:664 – 68.CrossRef Mawlieh BS, Shastry CS, Chand S. Evaluation of anti-diabetic activity of two marketed herbal formulations. Research J Pharm Tech. 2020;13:664 – 68.CrossRef
12.
go back to reference Mayer-Davis EJ, et al. Intensity and amount of physicial activity in relation to insulin sensitivity: the insulin resistance atherosclerosis study. J Am Med Assoc. 1998;279:669–74.CrossRef Mayer-Davis EJ, et al. Intensity and amount of physicial activity in relation to insulin sensitivity: the insulin resistance atherosclerosis study. J Am Med Assoc. 1998;279:669–74.CrossRef
13.
go back to reference Nsiah K, Shang VO, Boateng KA, Mensah FO. Prevalence of metabolic syndrome in type 2 diabetes mellitus patients. Int J Appl Basic Med Res. 2015;5:133–38.CrossRef Nsiah K, Shang VO, Boateng KA, Mensah FO. Prevalence of metabolic syndrome in type 2 diabetes mellitus patients. Int J Appl Basic Med Res. 2015;5:133–38.CrossRef
14.
go back to reference White UA, Tchoukalova YD. Sex dimorphism and depot differences in adipose tissue function. Biochim Biophys Acta. 2014 Mar;1842:377–92. White UA, Tchoukalova YD. Sex dimorphism and depot differences in adipose tissue function. Biochim Biophys Acta. 2014 Mar;1842:377–92.
15.
go back to reference Xiao J, Li Wu C, Gao YX, Wang SL, Wang L, Yun Lu Q, Wang XJ, et al. Prevalence of metabolic syndrome and its risk factors among rural adults in Nantong, China. Sci Rep. 2016;6:38089.CrossRef Xiao J, Li Wu C, Gao YX, Wang SL, Wang L, Yun Lu Q, Wang XJ, et al. Prevalence of metabolic syndrome and its risk factors among rural adults in Nantong, China. Sci Rep. 2016;6:38089.CrossRef
16.
go back to reference Bhat RA, Laway BA, Zargar AH. Prevalence of metabolic syndrome in Kashmir valley of Indian subcontinent. Indian J Med Sci. 2010;64:259–64.CrossRef Bhat RA, Laway BA, Zargar AH. Prevalence of metabolic syndrome in Kashmir valley of Indian subcontinent. Indian J Med Sci. 2010;64:259–64.CrossRef
17.
go back to reference Yadav D, Mahajan S, Subramanian SK, Bisen PS, Chung CH, Prasad GB. Prevalence of metabolic syndrome in type 2 diabetes mellitus using NCEP-ATPIII, IDF and WHO definition and its agreement in Gwalior Chambal region of Central India. Glob J Health Sci. 2013;17:5:142–55. Yadav D, Mahajan S, Subramanian SK, Bisen PS, Chung CH, Prasad GB. Prevalence of metabolic syndrome in type 2 diabetes mellitus using NCEP-ATPIII, IDF and WHO definition and its agreement in Gwalior Chambal region of Central India. Glob J Health Sci. 2013;17:5:142–55.
18.
go back to reference Sawant A, Mankeshwar R, Shah S, Raghavan R, Dhongde G, Raje H, et al. Prevalence of metabolic syndrome in urban India. Cholesterol. 2011;2011:920983.CrossRef Sawant A, Mankeshwar R, Shah S, Raghavan R, Dhongde G, Raje H, et al. Prevalence of metabolic syndrome in urban India. Cholesterol. 2011;2011:920983.CrossRef
19.
go back to reference Peterson PN, Spertus JA, Magid DJ, Masoudi FA, Reid K, Hamman RF, et al. The impact of diabetes on one year health status outcomes following acute coronary syndrome. BMC Cardiovasc Disord. 2006;6;41. Peterson PN, Spertus JA, Magid DJ, Masoudi FA, Reid K, Hamman RF, et al. The impact of diabetes on one year health status outcomes following acute coronary syndrome. BMC Cardiovasc Disord. 2006;6;41.
20.
go back to reference Zafar U, Khaliq S, Ahmad HU, Manzoor S, Lone KP. Metabolic syndrome: an update on diagnostic criteria, pathogenesis, and genetic links. Hormones (Athens). 2018;17:299–13.CrossRef Zafar U, Khaliq S, Ahmad HU, Manzoor S, Lone KP. Metabolic syndrome: an update on diagnostic criteria, pathogenesis, and genetic links. Hormones (Athens). 2018;17:299–13.CrossRef
21.
go back to reference Sharma KK, Mathur Mukul, Lodha S, Sharma SK, Sharma N, Gupta R. Study of differences in presentation, risk factors and management in diabetic and nondiabetic patients with acute coronary syndrome. Indian J Endocrinol Metab. 2016;20:354–58. Sharma KK, Mathur Mukul, Lodha S, Sharma SK, Sharma N, Gupta R. Study of differences in presentation, risk factors and management in diabetic and nondiabetic patients with acute coronary syndrome. Indian J Endocrinol Metab. 2016;20:354–58.
22.
go back to reference Supriya Simon A, Dinesh Roy D, Jayapal V, Vijayakumar T. Biochemical and genetic studies on cardiometabolic syndrome. Indian J Clin Biochem. 2010;25:164–68.CrossRef Supriya Simon A, Dinesh Roy D, Jayapal V, Vijayakumar T. Biochemical and genetic studies on cardiometabolic syndrome. Indian J Clin Biochem. 2010;25:164–68.CrossRef
23.
go back to reference Chiolero A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. 2008;87:801–09.CrossRef Chiolero A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. 2008;87:801–09.CrossRef
Metadata
Title
Association Between Metabolic Syndrome and Diabetes Mellitus According to International Diabetic Federation and National Cholesterol Education Program Adult Treatment Panel III Criteria: a Cross-sectional Study
Authors
Merlit James
Treesa P. Varghese
Raghav Sharma
Sharad Chand
Publication date
01-06-2020
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2020
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-020-00523-2

Other articles of this Issue 1/2020

Journal of Diabetes & Metabolic Disorders 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine